Lp(a) Mail-In Test, graded a measurement tool on Magellan — RNA-based therapies—and now a first oral inhibitor—lower Lp(a) by roughly 70–100% in trials, but cardiovascular outcome trials are still ongoing and no Lp(a)-specific drug is yet approved, so measuring it currently guides risk stratification more than treatment.
Source: JAMA 2009, PMID 19622820 ↗ · Diagnostics & Epigenetic Tests · How Magellan grades evidence · Study write-up · evidence confidence: medium
Lipoprotein(a), or Lp(a), is a low-density lipoprotein (LDL)-like particle in which an apolipoprotein(a) molecule is covalently bound to apolipoprotein B-100. Its blood concentration is roughly 80–90% genetically determined by variation in the LPA gene and stays relatively stable across a person's lifetime, while differing widely between individuals and populations. An Lp(a) test measures this concentration, which is not captured by a standard cholesterol panel. Elevated Lp(a) promotes atherosclerosis, inflammation, and valve calcification, and major guidelines now recommend measuring it at least once in every adult's lifetime to flag very high inherited levels.
Large meta-analyses, prospective cohorts, and Mendelian randomization studies establish elevated Lp(a) as a causal, independent risk factor for coronary heart disease, myocardial infarction, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis, with roughly one in five people carrying high levels; very high levels carry risk comparable to heterozygous familial hypercholesterolemia. The association is continuous and largely independent of LDL cholesterol, although effect sizes for stroke and all-cause mortality are more modest. RNA-based therapies—and now a first oral inhibitor—lower Lp(a) by roughly 70–100% in trials, but cardiovascular outcome trials are still ongoing and no Lp(a)-specific drug is yet approved, so measuring it currently guides risk stratification more than treatment. This evidence concerns the Lp(a) biomarker and its measurement in general, not this specific commercial mail-in test.
Peer-reviewed studies on the active compound — citations link to PubMed.
“continuous, independent, and modest associations of Lp(a) concentration with risk of coronary heart disease and stroke”
“high lipoprotein(a) concentrations predict 2- to 3-fold increases in risk”
“genetically predicted Lp(a) associated with an increased risk of incident atrial fibrillation”
“This meta analysis of prospective studies shows a clear association between elevated Lipoprotein (a) levels and increased risk of CHD. This effect is substantially higher in individuals with previous CHD. Our systematic review showed no evidence of an effect on stroke and all cause mortality.”
“These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.”
“In this individual-patient data meta-analysis of statin-treated patients, elevated baseline and on-statin lipoprotein(a) showed an independent approximately linear relation with cardiovascular disease risk.”
Research describes the active mechanism and is not a claim about this specific product.
Across large prospective cohorts and meta-analyses, lower grip strength is consistently…
Across large studies, dysregulated cortisol patterns track with worse health: a…
Large prospective cohorts and meta-analyses consistently link higher serum GGT, even…
Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature…
Yes — its active compound is linked to 19 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.